United States Vaccine Market Report and Forecast 2024-2032

United States Vaccine Market Outlook

The United States vaccine market attained a value of about USD 14.82 billion in 2023. The market is further expected to grow in the forecast period of 2024-2032 at a CAGR of 9.8%.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Increasing Deployment of mRNA Technology in Vaccine Development is Aiding the Market Growth

The initiation of vaccine development through mRNA technology is increasing research and development (R&D) activities owing to the prevalence of various infectious diseases, such as Ebola, Zika, and influenza, among others. This trend has been fuelled due to the emergence of SARS-CoV-2, which is surging the requirement for effective vaccines to prevent morbidity and fatality, which has driven the market.

As research activities to develop efficient vaccines were initiated, mRNA technology was leveraged to easily modify the sequencing of vaccines to enable their effectiveness against the mutations of the novel virus, which has driven the market growth. Moreover, the development of mRNA vaccines against COVID-19 infections by leading companies, such as Pfizer and Moderna, has fuelled the market growth. The increasing approvals of the novel COVID-19 mRNA vaccines have provided further impetus to the market growth. For instance, the Food and Drug Administration of the United States authorised the emergency use of Pfizer’s mRNA vaccine, BNT162b2, in December 2020.

Vaccine: Market Segmentation

A vaccine is a medicine that enables the suspension of killed or weakened microbes to enable the development of antibodies and prevent the risk of contraction of infectious disease. It provides active immunity from diseases to enhance the quality of life. The administration of vaccines, variously known as vaccination, is one of the most effective ways to prevent the spread of infectious diseases.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The major technologies of vaccine are:

• Recombinant and Conjugate Vaccine
• Inactivated Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Others

The market can be broadly categorised on the basis of its indications into:

• Pneumococcal Disease
• Influenza
• Human Papilloma Virus
• Meningococcal Disease
• Rotavirus
• Varicella, Measles, Mumps, and Rubella
• Diphtheria, Pertussis, and Tetanus (DPT)
• Polio
• Hepatitis
• Others

By end uses, the market is divided into:

• Paediatric Vaccine
• Adult Vaccine
• Travellers Vaccine

The EMR report looks into the regional markets of vaccine in the United States like New England, Mideast, Great Lakes, Plains, Southeast, Southwest, Rocky Mountain, and Far West.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rising Demand for Immunisation of Infants to Bolster the Market Growth of Vaccine in the United States

The rising demand for vaccines of pathogenic issues, diarrhoeal diseases, and parasitic adversaries, among others, is augmenting the industry growth. As the requirement of immunisation of infants to enhance the quality of life is surging, vaccines are increasingly deployed to prevent the risk of infectious diseases among children, hence fuelling the market growth. For instance, federally funded programs such as the Vaccines for Children (VFC) and Children’s Health Insurance Program (CHIP) offers free vaccination for underprivileged children. Moreover, the deployment of cutting-edge technologies to enable the swift development of vaccines is propelling the market growth.

The development of innovative vaccines that can be delivered through micro patches to enable efficient vaccination in infants is anticipated to augment the market growth. Advancements in biotechnology and genetic engineering are expected to lead to the determination of accurate structures of antigens, hence aiding in the development of more efficient vaccines.  In addition, the increasing concerns regarding the resurgence of COVID-19 infections and the emergence of a novel virus are projected to propel the growth of the vaccine industry in the forecast period.

Key Industry Players in the United States Vaccine Market

The report presents a detailed analysis of the following key players in the United States vaccine market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• GlaxoSmithKline plc
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• AstraZeneca plc
• Johnson & Johnson Services, Inc.
• Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report

United States Vaccine Market Report Snapshots

United States Vaccine Market Size

United States Vaccine Market Growth

United States Vaccine Companies